Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy

Table 1

siRNA cancer therapeutics in clinical trials.

Drug	Company	Vehicle	Target	Disease	Delivery route	Phase	Stage
CALAA-01	Calando Pharma	Cyclodextrin nanoparticle, Transferrin, PEG	M2 subunit of ribonucleotide reductase	Solid tumors	IV	I	Ongoing,; not recruiting
Atu027	Silence Therapeutics	Liposomes (Lipoplexes, Cationic lipid)	Protein kinase N3	Solid tumors	IV	I	Completed
ALN-VSP02	Alnylam Pharma	SNALP	VEGF and KSP	Solid tumors with liver involvement	IV	I	Completed
				Solid tumors	IV	I	Completed
TKM 080301	Tekmira Pharma	SNALP	Polo-kinase-1	Solid tumors	IV	I	Recruiting
				Solid tumors with liver involvement	IV	I	Completed
siRNA-EphA2-DOPC	M.D. Anderson Cancer Center	Liposomes (neutral liposomes)	EphA2	Solid tumors	IV	I	Not yet open
siG12D LODER	Silenseed Ltd	Polymer matrix (LODER polymer)	KRASG12D	Pancreatic ductal adenocarcinoma	EUS biopsy needle	I	Ongoing, recruiting
						II	Not yet open